Figure 1. Antitumor activity of selpercatinib in patients with
 RET -mutant MTC. Waterfall plots of the best
change in tumor size for (a) the PAS assessed by the IRC and (b) all
enrolled patients with MTC. Each bar represents an individual
patient. Notes: In the PAS (n = 26), one treatment-naïve patient with
RET-mutant MTC did not have an evaluable response. Among all
enrolled patients with MTC (n = 29), one patient did not have an
evaluable response and one had only non-target lesions. IRC, independent review committee; MTC, medullary thyroid cancer;
PAS, primary analysis set; RET, REarranged during Transfection.